30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
BCR-ABL1-like ALL (Ph-like ALL) is associated with a poor prognosis (5-year DFS of 60%) and is less common in pediatric B-cell ALL (3%) but is the most common subtype in adult ALL (25%); the
Ph-like ALL incidence is positively correlated with increasing age.
Abnormal kinase activation (ABL1, EPOR, JAK2, PDGFRB, EBF1, FLT2, IL7R, and SH2B3) is seen in 90% of Ph-like ALL and may be amenable to ABL1 TKI therapy.
CRLF2 gene rearrangement occurs in 50% of cases in Ph-like ALL and is associated with poor prognosis.